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Abstract
The biochemical landscape of lysine acetylation has expanded from a small number of proteins in the nucleus to a
multitude of proteins in the cytoplasm. Since the first report confirming acetylation of the tumor suppressor
protein p53 by a lysine acetyltransferase (KAT), there has been a surge in the identification of new, non-histone
targets of KATs. Added to the known substrates of KATs are metabolic enzymes, cytoskeletal proteins, molecular
chaperones, ribosomal proteins and nuclear import factors. Emerging studies demonstrate that no fewer than 2000
proteins in any particular cell type may undergo lysine acetylation. As described in this review, our analyses of
cellular acetylated proteins using DAVID 6.7 bioinformatics resources have facilitated organization of acetylated
proteins into functional clusters integral to cell signaling, the stress response, proteolysis, apoptosis, metabolism,
and neuronal development. In addition, these clusters also depict association of acetylated proteins with human
diseases. These findings not only support lysine acetylation as a widespread cellular phenomenon, but also impel
questions to clarify the underlying molecular and cellular mechanisms governing target selectivity by KATs. Present
challenges are to understand the molecular basis for the overlapping roles of KAT-containing co-activators, to
differentiate between global versus dynamic acetylation marks, and to elucidate the physiological roles of
acetylated proteins in biochemical pathways. In addition to discussing the cellular ‘acetylome’, a focus of this work
is to present the widespread and dynamic nature of lysine acetylation and highlight the nexus that exists between
epigenetic-directed transcriptional regulation and metabolism.
Introduction
DNA methylation and lysine modifications comprise
major epigenetic processes on chromatin, which alter
nucleosomal architecture leading to gene activation or
repression [1-3]. Dynamic post-translational modifications
(PTMs) occurring in the proximity of a gene promoter are
one of the hallmarks of epigenetic regulation of gene
expression [4]. Although an individual lysine residue may
undergo mutually exclusive multiple PTMs, including
acetylation, methylation, neddylation, ubiquitynation and
sumoylation, multiple lysines of a single protein can
undergo diverse modifications [5,6]. Functionally, these
site-specific PTMs, which are established during transcrip-
tional programming, impart flexibility to regulate cellular
processes in response to diverse physiological and external
stimuli. PTMs impact functional capabilities of a protein,
thus validating the notion that biological complexities are
not restricted only by the number of genes [7]. To
elucidate the functional consequences of a single PTM or
combinatorial PTMs occurring on chromatin, the histone
code hypothesis proposes to integrate the gene regulatory
ability of a site-specific histone modification within its bio-
logical context [8,9]. In quintessence, a site-specific PTM
serves as a mark to recruit a chromatin-associated protein
complex(es) that participates in controlling gene activity,
thereby, regulating cell fate decisions [10]. For instance,
within chromatin, depending on the site and degree of the
modification, lysine methylation can cause either gene
activation or repression; lysine acetylation on histones is
associated with chromatin relaxation contributing to gene
activation; and the biochemical outcome of lysine ubiqui-
tynation or sumoylation is dynamic turnover of proteins.
In addition, although the role of methylation in modulat-
ing non-histone proteins, including transcription factor
activity, is only beginning to be understood, acetylation of
transcription factors can affect their DNA-binding ability,
stability, nuclear translocation and capacity to activate tar-
get genes [7,11].* Correspondence: shiraz.mujtaba@mssm.edu
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Accumulating studies focusing on model systems of
viral infection and the DNA-damage response have sup-
ported the role for lysine acetylation in enhancing mole-
cular interactions between transcription factors and the
transcriptional machinery on a gene promoter, leading to
modulation of a specific downstream target [3,12-14].
Mechanistically, addition of an acetyl group to a lysine
residue alters the positive charge of the ε-amino group,
thereby impacting electrostatic properties that prevent
hydrogen bonding and generating a circumferential
hydrophobic milieu. Subsequently, this alteration of
charge could facilitate acetylation-directed molecular
interactions. Historically, almost four decades ago, acety-
lation of histones was first speculated to be involved in
gene transcription. However, it was not until 1996 that
one of the first lysine acetyltransferase (KAT), HAT-A
from Tetrahymena, was cloned and characterized [15].
Very recently, combinatorial approaches with high-affi-
nity acetyl-lysine antibodies, mass spectrometry (MS) and
stable-isotope amino-acid labeling (SILAC) techniques
detected almost 2000 acetylated proteins in the cell
[16,17]. Further, the functional implications of each of
these PTMs will have to be determined; one of the major
tasks will be to distinguish a dynamic acetyl mark(s) spe-
cific for a pathway from a set of pre-existing global
marks. Studies demonstrate that lysine acetylation can
initiate molecular interplay leading to at least one of the
two biochemical outcomes: 1) recruit co-activator com-
plexes via conserved modular domains such as bromodo-
mains; 2) engage co-repressor complexes through lysine
deacetylases (KDACs) [18,19]. Published studies have uti-
lized trichostatin A (TSA) or other KDAC inhibitors to
highlight the biochemical significance of acetylation
[20,21]. Long-term therapeutic aspirations stem from the
pharmacological inhibition of KDACs that provides clini-
cal benefits in models of human disease. Histone deacety-
lation reverts the electrostatic characteristics of
chromatin in a manner that favors gene repression. Inter-
estingly, a recent genome-wide chromatin immunopreci-
pitation analysis revealed preferential association of
KDACs with active genes, suggesting that KDACs do not
simply turn off genes, but rather function to fine-tune
gene expression levels [22].
Cellular-wide proteomic analyses on protein acetylation
revealed a large number of acetylated proteins, mostly
enzymes involved in intermediary metabolism in the cyto-
plasm as well as the mitochondrion [16,23,24]. These find-
ings support a larger role of acetylation extending beyond
the nucleus mainly toward the regulation of metabolic
enzymes by at least two mechanisms: 1) acetylation-
mediated modulation of metabolic enzymatic activity; and
2) influencing their protein stability [17,25,26]. Given the
frequent occurrence of metabolic dysregulation in human
diseases, including diabetes, obesity and cancer, acetylation
could play a pivotal role in the progression of these dis-
eases. Particularly in cancers, it is well known that the
transcriptional functions of the tumor suppressor p53 are
affected by alterations in tumor-cell metabolism [27,28].
Because enzymes that catalyze acetylation are also tran-
scriptional co-activators, which coordinate with transcrip-
tion factors in regulating gene expression–underscoring
the integration of transcription with metabolism–such
enzymes present potential therapeutic targets. The overall
goal of this review is to highlight the most recent advances
in the field of acetylation biology that could spark new
perspectives and illuminate novel research avenues.
The versatile and conserved nature of Lysine
acetylation
The versatile nature of the amino acid lysine is exhibited
not only by its ability to undergo a wide range of epige-
netic modifications implicated in chromatin signaling
networks but also by its indispensable structural role in
extracellular matrices. The ε-amino group participates in
hydrogen bonding and acts as a general base in catalysis.
This unusual chemical plasticity within a lysine residue
eliminates steric hindrance to allow histone-modifying
enzymes that are central to transcriptional regulation to
perform acetylation and methylation as well as subse-
quent deacetylation and demethylation (Figure 1).
Lysine acetylation was initially identified in histones, so
KATs and KDACs were referred to as histone acetyltrans-
ferases (HATs) and deacetylases (HDACs), respectively.
There are three major groups of KATs: Gcn5-related
N-acetyltransferases (GNATs); E1A-associated protein of
300 kDa (p300; KAT3A) and CBP (KAT3B); and MYST
proteins [10,29]. Known KDACs are divided into classes
I, II and IV and the sirtuin family (also known as class III
KDACs). In humans, there are KDAC1, -2, -3, and -8
(class I); KDAC4, -5, -6, -7, -9, and -10 (class II); and
KDAC11 (class IV) [30]. There are seven members of the
sirtuin family in humans (SIRT1-7) [22,31]. Wang and
colleagues [22] recently analyzed the genome-wide locali-
zation of KDACs and their KAT counterparts in human
immune cells. Surprisingly, KDACs were not recruited to
silenced gene promoters. Instead, both KATs and
KDACs were enriched on inactive promoters that had
methylation of histone H3 at lysine 4 (H3K4me) and
were also enriched on active promoters. The occurrence
of KDACs on promoters imply deacetylation, which will
prevent RNA polymerase II from binding to genes that
are standing by to be activated but should not yet be
switched on. For instance, KDACs might also contribute
to the removal of undesired basal acetylation. Collec-
tively, these results indicate a major role for KDACs in
the maintenance of gene activation.
Patel et al. Nutrition & Metabolism 2011, 8:12
http://www.nutritionandmetabolism.com/content/8/1/12
Page 2 of 12
Several studies have described acetylated proteins from
mouse liver, human leukemia cells, and more recently
from human liver cells [17,23,25]. Out of the 1047 acety-
lated proteins from human liver, 135 overlapped with
195 acetylated proteins from mouse liver. However, only
240 acetylated proteins were common between the
human liver and leukemia cells, suggesting that differen-
tial profiles of acetylated-proteins could be physiologi-
cally relevant and also cell-type-dependent [16]. In
leukemic cells, using high-resolution MS, 3600 lysine
acetylation sites were identified on 1750 proteins [16].
Our analysis of the supplementary data from that study
using the functional annotation clustering tool DAVID
6.7 showed that the lysine-acetylated proteins can be
categorized into more than 500 functional clusters (Addi-
tional file 1Table S1), thereby extending our knowledge
of the cellular events that are regulated by acetylation
[32,33]. This functional annotation clustering tool identi-
fies related genes or proteins by measuring the similarity
of their global annotation profiles based on the hypoth-
esis that if two genes have similar annotation profiles,
they should be functionally related. Using this rationale,
the method identifies broader gene groups whose mem-
bers share major biological features. Based on the output
generated by this tool the acetylated proteins were deter-
mined to be involved in the regulation of numerous pro-
cesses such as mRNA processing, proteolysis, GTP
binding, stress responses, regulation of cell death,
immune system development, neuron development and
differentiation, and regulation of the protein kinase cas-
cade. Interestingly, more than 500 acetylated unique pro-
teins with multiple acetylation sites were categorized as
being involved in chromatin-templated processes (Figure
2). Functional annotation clustering revealed the acety-
lated proteins to be involved in regulation of Parkinson’s
disease, Huntington’s disease, Alzheimer’s disease and
glycogen storage disease. An important functional cluster
that emerged from our analyses included more than
50 acetylated proteins involved in various types of can-
cers. KAT3B, retinoblastoma and tumor suppressor p53
figured prominently in the list of proteins implicated in
human diseases (Additional file 2 Table S2).
Figure 1 A lysine residue targeted by co-factors and enzymes mediating epigenetic events that regulate cellular processes.
Figure 2 Graphic and qualitative representation of the
functional distribution of acetylated proteins in a human
cancer cell line.
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Lysine acetylation is a prevalent modification in enzymes
that catalyze intermediary metabolism, and our analyses
extended the scope of this regulation [17]. Lysine acety-
lated proteins are involved in the metabolism of carbo-
hydrates, lipids, nucleotides, amino acids, secondary
metabolites, and xenobiotics. Acetylation also regulates
the relative activities of key enzymes controlling the
course of glycolysis versus gluconeogenesis, and the
branching between the citrate cycle and glyoxylate
bypass. This modulation within metabolic pathways is
directed by a KAT and KDAC pair whose expression
levels are synchronized according to growth conditions.
Reversible acetylation of metabolic enzymes ensures
rapid cellular responses to environmental changes
through prompt sensing of cellular energy status and
flexibly altering reaction rates.
Until very recently, lysine acetylation was known only
in eukaryotic cellular processes, although its existence in
prokaryotes was predicted. Substantiating this idea, very
recently, it was shown that reversible lysine acetylation
regulates acetyl-coenzyme A synthetase activity in Sal-
monella enterica [25]. Acetylation of metabolic enzymes
that depend on a carbon source indicates that acetyla-
tion may mediate adaptation to various carbon sources
in S. enterica, which has only one major bacterial pro-
tein acetyltransferase, Pat, and one nicotinamide adenine
dinucleotide (NAD+)-dependent deacetylase, CobB. To
determine whether and how lysine acetylation globally
regulates metabolism in prokaryotes, Zhao et al. deter-
mined the overall acetylation status of S. enterica pro-
teins under fermentable glucose-based glycolysis and
under oxidative citrate-based gluconeogenesis [17].
Moreover, those authors demonstrated that key meta-
bolic enzymes of S. enterica were acetylated in response
to different carbon sources concomitantly with changes
in cell growth and metabolic flux.
In addition to the epigenetic modifications on lysines
that occur in chromatin, collagen contains hydroxyly-
sine, which is derived from lysine by lysyl hydroxylase.
Furthermore, allysine is a derivative of lysine produced
by the action of lysyl oxidase in the extracellular matrix
and is essential in crosslink formation and stability of
collagen and elastin. Similarly, O-glycosylation of lysine
residues in the endoplasmic reticulum or Golgi appara-
tus is used to mark certain proteins for secretion from
the cell. Interestingly, lysine is metabolized in mammals
to give acetyl-CoA, via an initial transamination with
a-ketoglutarate, which is then utilized as a substrate by
KATs. Bacterial degradation of lysine yields cadaverine
by decarboxylation. Although histidine and arginine are
also basic amino acids, they are not subjected to PTM
as is lysine. Taken together, these findings signify that
mechanisms regulating metabolism may be evolutiona-
rily conserved from bacteria to mammals. Furthermore,
characterization of acetylation-mediated regulatory
mechanisms in bacteria would offer new perspectives in
advancing our understanding of many hitherto unknown
biological processes. In the remainder of this article, we
concentrate on a few important proteins that require
acetylation to execute their functions and which have
been widely investigated but still remain a subject of
intense of biochemical research.
The acetylation-directed transcriptional program
Acetylation engendered chromatin milieu on gene
regulation
The earliest explanation of histone acetylation was in the
physicochemical context that nucleosomes and chromatin
impose a barrier to transcription. Subsequently, it became
apparent that lysine acetylation neutralizes the positive
charges on histone tails (Figure 3), relaxing their electro-
static grip on DNA to cause nucleosomal remodeling that
exposes transcription factor binding sites [34]. Further-
more, because acetylated lysine moieties on histone tails
could serve as recruitment sites for bromodomain-contain-
ing cofactors or reversal of charge by KDACs, this not only
suggested an additional mechanism for KAT-directed gene
activation [35], but also established that acetylation, like
phosphorylation, creates a new scaffold to recruit proteins
to the nucleosome. Notably, in charge-neutralization
models, acetylation of multiple lysine residues–that is,
hyper-acetylation–on a single histone tail should produce a
stronger effect than mono-acetylation. By contrast, in bro-
modomain-recruitment models, in which adjacent amino
acids determine specificity, a single lysine residue on a his-
tone tail is paramount, and possible hyper-acetylation of
the entire tail may not be expected to contribute further to
recruitment [36]. It is also possible that for a specific lysine
residue, both modalities of acetylation may be physiologi-
cally relevant and apply in different circumstances, as sug-
gested from in vitro studies of H4-K16 acetylation [37,38].
Moreover, adding to the complexities of acetylation, it can-
not be ruled out that acetylated moieties may also recruit
KDACs to regulate tightly and temporally transcriptional
activation, as mentioned above.
The puzzling cross-talk on chromatin between post-
translationally modified sites
Acetylation versus methylation
A growing body of evidence suggests that independent
of their proximity, co-existing histone modifications can
have synergistic or antagonistic effects on gene expres-
sion. This also highlights that epigenetic marks are not
deposited or recognized in isolation but comprise a
complex and interrelated collection of modifications at
adjacent residues on a given nucleosome of a gene pro-
moter. The correlation between different histone modifi-
cations is particularly clear for acetylation of histone H3
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(Figure 3) and methylation of histone H3 at lysine 4.
This is consistent with the observed co-localization of
these marks, which show correlated distribution patterns
both on a chromosome-wide scale during X inactivation
and over the coding regions of individual genes [39,40].
These correlations may arise due to physical links
between histone-modifying enzymes such that they are
co-recruited to the same loci. Both KMT2A/MLL1, a
lysine methyltransferase (KMT) that can generate
H3K4me marks [41], and Chd1, the chromatin remode-
ler that is subsequently recruited by this methyl mark,
associate with KAT activities [42,43], whereas the LSD1
complex that removes some of these methyl marks con-
tains the lysine deacetylases KDAC1 and KDAC2 [44].
However, the interaction could also arise due to the
mechanism of action of these enzymes. For example, the
SET domain of KMT2A has a preference for acetylated
substrates [41].
Acetylation versus phosphorylation
Multiple cellular processes are associated with histone
phosphorylation: DNA damage induces phosphorylation
on serine 139 of H2A (H2AS139p) [10,45]; transcription,
upon mitogenic stimulation, on H3S10p [10]; mitosis on
H3S10p and H3S28p; apoptosis, depending on the stimulus
used, on H4S1p, H3S10p, H2BS32p, and H2AS32p [9,10].
Serum stimulation induces the PIM1 kinase to phosphory-
late pre-acetylated histone H3 at the FOSL1 enhancer [46].
The adaptor protein 14-3-3 binds the phosphorylated
nucleosome and recruits KAT8/MOF, which triggers acet-
ylation of H4K16 [47]. Histone crosstalk generates the
nucleosomal recognition code composed of H3K9ac/
H3S10p/H4K16ac that determines the nucleosome plat-
form for binding of the bromodomain protein BRD4
[48,49]. Recruitment of the positive transcription elonga-
tion factor b (P-TEFb) via BRD4 induces the release of the
promoter-proximal paused RNA polymerase II and
increases its processivity. Thus, the single phosphorylation
on H3S10 at the FOSL1 enhancer triggers a cascade of
events which activates transcriptional elongation. Increas-
ing evidence also show that several types of modifications
are linked and, in particular, one modification may influ-
ence the presence of a nearby modification [9,10,50]. This
has been demonstrated for H3K14ac and H3S10p on the
histone H3 tail, as well as, for H3S10p and H3K9me on the
same tail [51]. Whereas the first pair of modifications has
been coupled to activation of gene expression, increasing
evidence indicates that H3K9me results in decreased
H3S10p and is thereby responsible for silencing.
Figures 3 Lysine acetyltransferases involved in acetylating histone proteins. In chromatin, A denotes acetylation; M, methylation; P,
phosphorylation and U, ubiquitination.
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Impact of acetylation on the functioning of transcription
factors
The tumor suppressor protein p53 functions as a tran-
scription factor to orchestrate a transcriptional program
that controls many target genes during a wide variety of
stress responses [52,53]. After sensing a genetic aberra-
tion (such as DNA damage), the sequence-specific
DNA-binding ability of p53 enables it to directly partici-
pate in controlling target gene transcription to alter cel-
lular responses. In addition to being a DNA-binding
transcription factor, p53, following stress, undergoes
extensive PTMs to enhance its function as a transcrip-
tion factor in controlling cellular decisions that could
culminate in cell-cycle arrest, senescence or apoptosis
[52,53] (Figure 4). Interestingly, p53 has a short half-life;
however, depending on the nature of the stress, the cell
type and the profile of PTMs rendered, p53 will
promptly execute a transcriptional program beneficial to
the cell [54]. In addition, through protein-protein inter-
actions, p53 can bind to and recruit general transcrip-
tion proteins, TAFs (TATA-binding protein-associated
factors), to induce transcription of target genes [55-57].
Recent experiments have shown that p53 can also
engage with KATs, including KAT3B, KAT3A, KAT5/
Tip60 and KAT2B/PCAF to the promoter region of
genes [58-60].
In 1997, Gu and Roeder showed that acetylation of
p53 on its C-terminal lysines by KAT3A/3B is crucial
for p53 activation during DNA damage [59,60]. Subse-
quently, the biochemical significance of p53 acetylation
was established in cancer cell lines under various geno-
toxic stresses and oncogenic Ras activation that lead to
the interaction of acetylated p53 with KAT3A and PML
[61-63]. In parallel, it was proposed that p53, upon acti-
vation, undergoes a wave of phosphorylation on its
N-terminus that precludes its degradation by MDM2
and concomitantly brings in KAT3A/3B to acetylate the
C-terminal end of p53 [64,65]. At this stage, KAT3A/
3B-catalyzed p53 acetylation was implicated in enhan-
cing p53’s DNA-binding ability, nuclear localization and
co-activator recruitment functions [11]. Later, KAT2B
was also shown to acetylate lysine 320 of human p53
and lysine 317 of mouse p53 [62]. Recent identification
of the p53K120ac site in the p53 DNA-binding region
supports a direct role for acetylation in p53- DNA inter-
actions. Lysine 120 on p53 is acetylated by KAT5 and/
or KAT8/MOF [58,66]. Taken together, the impact of
acetylation on p53 function can be attributed to the
inhibition of nonspecific DNA-binding, recruitment of
bromodomain-containing co-activators for target-gene
activation, and modulation of KDAC activity to regulate
target-gene activation. Nevertheless, the most puzzling
aspect of p53 PTMs remains to be clarified: the
mechanism by which acetylation of the C-terminus of
p53 produces mutually exclusive lysine methylation or
ubiquitination. Recent studies revealed that p53K370,
K372 and K382 can also be methylated, indicating
cross-regulation between acetylation, methylation and
ubiquitynation. One recent study speculates that
p53K372me recruits KAT5 through its chromodomain
to mediate p53K120ac [67]. Clearly, the biochemical
nature of the multi-layered and mutually exclusive mod-
ifications of the p53 C-terminus is complex. It is also
puzzling that, despite association of p53 mutations with
at least 50% of human cancers, Li Fraumeni syndrome is
the only disease where p53 dysfunction is known to be
directly involved. Adding further complexity, homozy-
gous mice with seven lysines on p53 mutated to arginine
are viable and apparently phenotypically normal [68].
Similarly, in mice with six K®R mutations in p53,
expression of the protein was unaffected [69].
Since the discovery of p53 acetylation 15 years ago,
numerous studies have revealed quite unexpected com-
plexity. However, these studies also provide valuable les-
sons for investigating acetylation of other proteins. One
realization is that, like histone acetylation, p53 acetyla-
tion does not act alone but forms an integral part of an
intricate, multisite modification program. One of the
strongest pieces of evidence to support the idea that the
PTMs of p53 are relevant to the p53 regulatory mechan-
ism is the fact that KDAC inhibitors have been shown
to simultaneously increase the levels of acetylated p53
and induce apoptosis or senescence in cancerous and
normal cells [70]. Although the PTMs of p53 are cer-
tainly important, our ability to properly identify which
ones are relevant under what conditions remains
rudimentary.
In addition to p53, transcription factors of the nuclear
factor kappa-light-chain-enhancer of activated B cells (NF-
B) family are essential regulators of the inflammatory and
Figures 4 Lysine acetyltransferases responsible for mediation
of the stress response by p53. The green flag stands for
acetylation and the yellow ball-stick represents phosphorylation of
p53 during stress.
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immune responses [71]. Acetylation of RelA/p65 by
KAT3A/3B probably is associated with transcriptional
activation [72,73]. Although multiple acetylation sites on
p65 protein have been reported (e.g., lysine 310, 314, 315),
it’s the acetylation of lysine 310 that has been observed to
enhance transcriptional activity without altering binding
to DNA or IB [74-76]. Acetylation of lysine 310 is
blocked either in the absence of serine 276 phosphoryla-
tion or by overexpression of catalytically inactive PKAc
[73]. Thus, it is speculated that phosphorylation of serine
276 on p65 triggers recruitment of KAT3A/3B that next
acetylates lysine 310 on p65. It is further proposed that, in
addition to p65 phosphorylation, IKKa also promotes
acetylation through direct phosphorylation of N-CoR/
SMRT, which displaces KDAC3 from the SMRT corepres-
sor complex [77]. IKKa is found associated with the B
sites of NF-B-responsive genes and stimulus-induced
phosphorylation of H3 serine 10 [74,78].
In addition to cellular transcription factors, viral pro-
teins interact to manipulate the function host’s nuclear
factors. It is established that control of the immune net-
work by a human pathogenic virus starts with coopta-
tion of the host’s transcription and replication
machineries. Interestingly, KATs also acetylate viral pro-
teins; and subsequent molecular events occurring post-
acetylation of viral proteins aid in control of the host’s
transcriptional machinery [12,79]. The best-known
example is HIV transactivator protein Tat, which under-
goes acetylation on lysines 28 and 50 to promote rapid
replication of the HIV proviral genome [79,80]. Acetyla-
tion-mediated interactions between the cellular tran-
scription machinery and viral proteins offer new
therapeutic avenues, especially since anti-HIV drugs tar-
geted against HIV proteins have been reported to cause
drug resistance [80]. Taken together, acetylation of
chromatin and transcription factors is a widespread phe-
nomenon that not only facilitates gene regulation but
also participates in numerous other cellular processes.
Nexus Linking Dysregulation of Metabolism and p53
Transcription Functions in Cancers
The availability of proper nutrients directly supports the
synthesis of biological macromolecules that promote the
growth and survival of cells and the organism. In con-
trast, starvation could limit cellular growth in order to
sustain self-survival by using energy primarily from the
breakdown of macromolecules rather than by synthesis.
Clearly, metabolic pathways are tightly regulated to pro-
duce energy to allow efficient cellular growth and survi-
val programs [81]. Evidently, tumor cells depend on
metabolic changes for their continued growth and survi-
val, and these alterations enhance the uptake of glucose
and glutamine by cancer cells [82]. Therefore, compo-
nents of metabolic pathways could provide new oppor-
tunities to explore potential therapeutic targets in the
treatment of malignant disease. In most normal cells,
the tricarboxylic acid (TCA) cycle drives the generation
of ATP in the presence of oxygen (O2), a process
known as oxidative phosphorylation. However, under
conditions of limiting O2 or when energy is needed
rapidly, glycolysis becomes the preferred route of energy
production [83]. The preference of cancer cells to
employ glycolysis may be a sign of response to hypoxia,
which occurs as the tumor outgrows the blood supply.
Although p53 can be activated during many stressors, it
is speculated that hypoxia is indeed one of them. In cel-
lular responses to hypoxia that involve the transcription
factor hypoxia inducible factor (HIF), it has been shown
that induction of p53 under low O2 concentration may
trigger HIF-p53 interaction [84]. In addition, reduced
nutrient or energy levels fail to stimulate both the AKT-
mTOR pathway and AMP-activated protein kinase,
which responds to an increased AMP/ATP ratio, result-
ing in p53 activation [85,86]. Furthermore, AKT acti-
vates MDM2 that regulates p53 stability; therefore,
reduced AKT function will preclude MDM2 negative
regulation of p53, leading to p53 activation under low-
nutrient conditions. Malate dehydrogenase that converts
malate to oxaloacetic acid in the TCA cycle has been
shown to interact with p53 during deprivation of cellu-
lar glucose levels [87]. Okorokov and Milner noted that
ADP promoted and ATP inhibited the ability of p53 to
bind DNA [88]. Several studies have also documented
that p53 has the capability of slowing down the glycoly-
tic pathway to control the growth of cancerous cells by
inhibiting the expression of glucose transporters [89].
Furthermore, although the underlying mechanism is still
unclear, p53 can also inhibit NF-B-mediated pro-
survival pathways by limiting the activity of IB kinase a
and IB kinase b functions [90]. Collectively, these find-
ings indicate that a lack of nutrients and deregulation of
nutrient-sensing pathways can each modulate a p53
response and that combinations of these abnormalities
during tumor progression amplify the protective p53
response.
Acetylation and regulation of metabolic enzymes
Our analysis by functional clustering of the “lysine acet-
ylome” revealed that at least 92 proteins were involved
in metabolic events and energy production, including
the TCA cycle, glycolysis, pyruvate metabolism, and
fatty acid metabolism (Figure 5). Furthermore, as shown
in Figure 6, a significant number of enzymes and the
respective pathways in which they are implicated could
be regulated by acetylation. For instance, 24 proteins in
the TCA pathway can be acetylated (Additional file
3Table S3). Recently, it was reported that the activities
of key enzymes regulating the choice of glycolysis versus
gluconeogenesis and the branching between the TCA
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cycle and glyoxylate bypass could possibly be regulated
by acetylation [25]. In this context, acetyl coenzyme A
(Ac-coA) is particularly important owing to its unique
role as the acetate donor for all cellular acetylation reac-
tions. In mammalian cells, Ac-coA is synthesized in two
pathways. In the first pathway, Ac-coA synthetase con-
denses acetate and coenzyme A into Ac-coA. In the sec-
ond pathway, energy from hydrolyzed ATP is utilized by
ATP-citrate lyase (ACL) to convert citrate, a TCA cycle
intermediate, and coenzyme A into Ac-coA and oxaloa-
cetate. Cytoplasmic Ac-coA serves as a building block
for lipids, whereas nuclear Ac-coA contributes to acety-
lation of chromatin and its associated proteins. This
demarcation within Ac-coA metabolism is necessitated
by cellular need of the coenzyme. Very recently, it was
demonstrated that histone acetylation in several human
cell lines relies primarily on ACL activity, thus linking
the TCA cycle, glycolysis and intracellular energy status
to gene activity [91]. Abrogation of ACL activity results
in alteration of global histone acetylation and gene tran-
scription. Using gene knockdown strategies, it was
determined that ACL is the major source of Ac-coA for
histone acetylation under normal growth conditions.
However, acetate supplementation following cellular
deprivation of ACL is able to rescue histone acetylation,
suggesting that Ac-coA production by Ac-coA synthe-
tase can compensate for the decrease in ACL activity,
which is dependent upon the availability of acetate. This
mechanism may allow the acetate that is generated dur-
ing histone deacetylation to be recycled back to Ac-coA.
Hence, because the pool of Ac-coA for epigenetic
control arises from the TCA cycle and is influenced by
energy flux, the metabolic status of cells is intertwined
with gene transcription. Importantly, given the continu-
ous requirement for the high-energy compounds Ac-
coA, S-adenosyl methionine (SAM) and coenzyme NAD
(or NAD+) for chromatin modifications, it is of high
priority to investigate whether the abundance of the lat-
ter two compounds also contributes to transcriptional
regulation via epigenetic mechanisms.
Similar to Ac-coA, NAD is a key compound that cap-
tures electrons in the form of hydride during glycolysis
and the TCA cycle. In contrast to many reactions in
which NAD is the essential coenzyme and only under-
goes a change in redox state, in sirtuin-mediated deace-
tylation reactions NAD is hydrolyzed into nicotinamide
and O-acetyl-ribose. The former compound is a potent
inhibitor of sirtuin KDAC activity, whereas the latter is
a signaling molecule [92]. Because of the obligatory
need of sirtuins for NAD in catalysis and their suscept-
ibility to nicotinamide inhibition, the activity of sirtuins
is controlled by the intracellular ratio of NAD to NADH
[93,94]. During each cycle of glycolysis and TCA, in
which cells derive energy from glucose and pyruvate
breakdown, NAD is reduced into NADH, thus decreas-
ing the NAD:NADH ratio that inhibits sirtuin activity.
Conceptually, this reduction of sirtuin function may
then be compensated for by downregulation of Ac-coA
synthetase, due to its inactivation by acetylation. Fluc-
tuation of NAD abundance modulates the activity of sir-
tuins that act on acetylated chromatin and transcription
factors.
Histone deacetylation not only represses transcription,
but also inhibits recombination. One of the functions of
yeast sirtuin Sir2p is to suppress the formation of rDNA
extrachromosomal circles that have been postulated to
be related to cellular senescence [95]. Thus, the metabo-
lism and availability of NAD may impact both the gen-
ome and cellular physiology in a multitude of ways,
including global and local changes in nucleosomal orga-
nization and the functions of transcription factors regu-
lated by lysine acetylation.
Potential of targeting acetylation
The molecular events that follow acetylation could lead
to recruitment of either bromodomain-containing pro-
teins or KDACs [9,35]. Therefore, on the one hand, the
enzymes that catalyze acetylation are obvious targets of
intervention; on the other hand, proteins that interact
with the acetylated-lysine moiety could also be poten-
tial targets [35,96]. With respect to KATs, two natural
products, anacardic acid and garcinol (a polyprenylated
benzophenone), are reported to inhibit both KAT3A/
3B and KAT2B in the 5-10 micromolar range in vitro
[97-99]. In contrast, curcumin displays selective activity
Figure 5 Role of lysine acetylation in enzymes involved in
intermediary metabolism. The pyramid provides an overview of
the involvement as well as overlapping roles of metabolic enzymes
such as pyruvate dehydrogenase, acetyl coA synthetase and
pyruvate kinase in four different metabolic pathways.
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against KAT3A/3B but not KAT2B [99]. Subsequent
studies suggest that anacardic acid may be a broad-
spectrum HAT inhibitor, as it also interferes with the
KAT5 [100]. Isothiazolones were identified in a high-
throughput screen as inhibitors of KAT2B and KAT3A/
3B [101]. These compounds could be broadly useful as
biological tools for evaluating the roles of HATs in
transcriptional studies and may serve as lead agents for
the development of novel anti-neoplastic therapeutics.
Recent studies show that small molecules designed
against the acetyl-lysine-binding hydrophobic pocket of
conserved bromodomains affect transcriptional regula-
tion and other cellular processes in cancer cells
[102,103]. Furthermore, small-molecule modulators of
KDACs have already emerged as promising therapeutic
agents for cancer, cardiac illness, diabetes, and neuro-
degenerative disorders. Hence, studies focusing on
lysine acetylation as well as molecular events that
follow acetylation could identify non-histone targets for
KAT- and KDAC-modulating compounds as well as
illuminate molecular basis of signaling on chromatin
and unravel new avenues to improve the efficacy of
related therapeutic agents.
Conclusions and future perspectives
Evidently, many acetylated proteins are not only key com-
ponents within nuclear processes, but also play crucial
roles in signaling pathways, such as DNA damage
response, immune network and inflammation. This has
propelled the idea that instead of phosphorylation being
the major contributor, signaling pathways are possibly
controlled by the synchronized actions of phosphorylation,
acetylation, and several other PTMs. Although acetylation
regulates the activity of metabolic enzymes, the role of
phosphorylation in conjunction with acetylation in meta-
bolic pathways is not clear. However, what is clear is that
Figure 6 An integrated view of the metabolic processes (fatty acid biosynthesis, glycolysis, gluconeogenesis and amino acid
metabolism) that converge on the citric acid cycle. Red stars represent lysine-acetylated metabolic enzymes and the red box highlights the
critical metabolic products integrated into various metabolic pathways. Highlighted enzymes with their respective EC numbers are: pyruvate
dehydrogenase (EC 1.2.4.1), dihydrolipoyl dehydrogenase (EC 1.8.1.4), pyruvate carboxylase (EC 6.4.1.1), malate dehydrogenase (EC 1.1.1.37),
fumarate hydratase (EC 4.2.1.2), citrate (Si)-synthase (EC 2.3.3.1), ATP citrate synthase (EC 2.3.3.8), aconitate hydratase (EC 4.2.1.3), isocitrate
dehydrogenase (NADP+) (1.1.1.42), isocitrate dehydrogenase (NAD+) (1.1.1.41), succinate dehydrogenase (1.3.5.1), succinate–CoA ligase (6.2.1.4;
GDP forming), and succinate–CoA ligase (6.2.1.5; ADP forming).
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lysine acetylation definitely expands the plasticity within
the metabolic and cellular signaling networks. This notion
is reinforced by the recent analyses of the “lysine acety-
lome” explicated above, which broadened the scope of
acetylation-mediated regulation through an expansive
clustering into diverse functional groups. This list offers
new insights into the role of acetylation and possible
routes to dissect its mechanism, especially in regulation of
diseases like cancer and neurodegenerative disorders.
Meanwhile, proteomic surveys by MS will continue to
identify new acetylated proteins, which along with effi-
cient mapping of acetylation sites by MS should reveal
additional sites [104]. For instance, accumulating studies
on p53 acetylation indicate that, subsequent to in vitro
biochemical characterization, cell lines and genetically
altered mouse models will be especially effective for
characterizing the biological functions associated with
particular lysine PTMs [105]. Most importantly, such
approaches will facilitate mapping within signaling path-
ways that are regulated by reversible acetylation. One
pertinent question is how such modifications interact
with other PTMs within the same or different protein(s)
and form dynamic programs for regulating cellular
functions under normal and pathological settings.
Within the acetylproteome, the functional impact of
lysine acetylation is context-dependent and varies from
protein to protein. As in histones, the molecular inter-
play of lysine acetylation with other PTMs, either ago-
nistically or antagonistically, generates codified
molecular signaling programs that are crucial for gov-
erning the functions of various nuclear and cytoplasmic
proteins [9,106-108].
Additional material
Additional file 1: Functional clusters were generated from the list of
lysine-acetylated proteins using the DAVID 6.7 bioinformatics
resources functional annotation tool. The acetylated proteins are
distributed into 526 functional clusters generated by the software using
a heuristic fuzzy clustering concept that measures relationships among
the annotation terms based on the degree of their co-association to
cluster similar annotations into functional annotation groups. The
annotation clusters are assigned “enrichment scores” in decreasing order
of occurrence that are quantitatively measured by some common and
well-known statistical methods, including Fisher’s exact test, binomial
probability and hypergeometric distribution.
Additional file 2: Lysine-acetylated proteins involved in different
forms of cancers. The list of proteins includes heat-shock family
members, kinases and transcription factors.
Additional file 3: List of lysine-acetylated proteins associated with
enzymes involved in metabolic pathways.
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